|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM313521824 |
| 003 |
DE-627 |
| 005 |
20231225150745.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108554
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1045.xml
|
| 035 |
|
|
|a (DE-627)NLM313521824
|
| 035 |
|
|
|a (NLM)32777270
|
| 035 |
|
|
|a (PII)S1521-6616(20)30577-5
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Rapisarda, L
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Varicella zoster immunity loss in multiple sclerosis patient treated with ocrelizumab
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.06.2021
|
| 500 |
|
|
|a Date Revised 04.12.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Ocrelizumab is a novel humanized anti-CD20 antibody used for treatment of relapsing remitting and primary progressive multiple sclerosis with evidence of inflammatory activity. Guidelines suggest assessing vaccination status and eventually vaccinate patients with multiple sclerosis before new disease modifying therapy initiation. However, there are not any specific recommendations about vaccinal immunity reassessment after ocrelizumab injection. We describe the case of a patient who loss varicella zoster vaccinal immunity after the first ocrelizumab infusion. It is advisable to reassess vaccinal immunity to isolate non-immune patients and to adopt suitable preventive measures, including close contacts vaccination and avoidance of contacts with active infection
|
| 650 |
|
4 |
|a Case Reports
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Immunity
|
| 650 |
|
4 |
|a Multiple sclerosis
|
| 650 |
|
4 |
|a Ocrelizumab
|
| 650 |
|
4 |
|a Varicella zoster
|
| 650 |
|
7 |
|a Anti-Inflammatory Agents
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Monoclonal, Humanized
|2 NLM
|
| 650 |
|
7 |
|a Antigens, CD20
|2 NLM
|
| 650 |
|
7 |
|a ocrelizumab
|2 NLM
|
| 650 |
|
7 |
|a A10SJL62JY
|2 NLM
|
| 700 |
1 |
|
|a Valentino, P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Barone, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Torti, C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a La Gamba, V
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fortunato, F
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sammarra, I
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gambardella, A
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 223(2021) vom: 15. Feb., Seite 108554
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:223
|g year:2021
|g day:15
|g month:02
|g pages:108554
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108554
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 223
|j 2021
|b 15
|c 02
|h 108554
|